News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Profectus BioSciences, Inc. Receives $5.6M Grant to Develop a Vaccine to Protect Humans against Infection with Nipah/Hendra Viruses


5/9/2012 10:26:42 AM

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a grant under the Partnerships for Biodefense RFA from the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.6M award supports the preclinical development of Hendra virus soluble G (HeV-sG) as a vaccine for use in humans against either Nipah or Hendra virus infection.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES